Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Dupont Capital Management Corp Takes Position in Albireo Pharma Inc (NASDAQ:ALBO)
08:48pm, Sunday, 09'th Aug 2020
Dupont Capital Management Corp purchased a new stake in Albireo Pharma Inc (NASDAQ:ALBO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund pur
Albireo Reports Q2 2020 Financial Results and Provides Business Update
11:30am, Thursday, 06'th Aug 2020
— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transac
Traders Buy High Volume of Call Options on Albireo Pharma (NASDAQ:ALBO)
01:50am, Wednesday, 05'th Aug 2020
Albireo Pharma Inc (NASDAQ:ALBO) saw unusually large options trading on Monday. Traders purchased 2,232 call options on the stock. This represents an increase of 1,154% compared to the typical daily v
Albireo to Present at the William Blair Biotech Focus Conference 2020
08:01pm, Thursday, 30'th Jul 2020
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron
Albireo to Report Q2 2020 Financial Results on August 6
12:00pm, Thursday, 30'th Jul 2020
— Conference call and webcast to be held at 10:00 a.m. ET — BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease compa
3 “Strong Buy” Pharma Stocks With Fast-Approaching Catalysts
03:42am, Tuesday, 28'th Jul 2020
Given the widespread market volatility, some investors are seeking refuge in more defensible stocks. However, this certainly doesn’t apply to every Wall Street observer. A select group remains ready
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Albireo Pharma Target of Unusually Large Options Trading (NASDAQ:ALBO)
02:02am, Wednesday, 22'nd Jul 2020
Albireo Pharma Inc (NASDAQ:ALBO) was the recipient of some unusual options trading on Monday. Investors bought 2,072 put options on the company. This is an increase of approximately 1,401% compared to
Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe
12:00pm, Monday, 20'th Jul 2020
BOSTON, July 20, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the.
Albireo Pharma (NASDAQ:ALBO) Trading 7.5% Higher Following Analyst Upgrade
01:16am, Sunday, 19'th Jul 2020
Albireo Pharma Inc (NASDAQ:ALBO) shares traded up 7.5% during trading on Friday after HC Wainwright raised their price target on the stock from $62.00 to $64.00. HC Wainwright currently has a buy rati
Albireo Pharma (ALBO) Initiated with a Buy at H.C. Wainwright - Markets
02:48pm, Thursday, 16'th Jul 2020
H.C. Wainwright analyst Ed Arce initiated coverage with a Buy rating on Albireo Pharma (ALBO – Research Report) today and
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
05:43pm, Wednesday, 15'th Jul 2020
Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
Albireo Pharma (ALBO) Gets a Buy Rating from Wedbush - Markets
05:59pm, Tuesday, 14'th Jul 2020
Wedbush analyst Liana Moussatos maintained a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price
Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Biliary Atresia
11:30am, Tuesday, 14'th Jul 2020
— BOLD is first-ever pivotal trial for biliary atresia —— Trial expands odevixibat’s development program into second rare cholestatic liver disease —BOSTON, July 14, 2020 (GLOBE NEWSWIRE) --
Why Albireo Pharma's (NASDAQ:ALBO) CEO Pay Matters
01:57pm, Monday, 13'th Jul 2020
This article will reflect on the compensation paid to Ron Cooper who has served as CEO of Albireo Pharma, Inc...
